title: Biological agents and psoriatic epidermis: what are we ultimately targeting?
authors.forename: M
authors.initials: M
authors.lastname: Heenen
authors.forename: T
authors.initials: T
authors.lastname: Simonart
mesh_terms: D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines / Q000187:drug effects; D004359:Drug Therapy, Combination; D004817:Epidermis / Q000187:drug effects* / Q000276:immunology; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D015603:Keratinocytes / Q000187:drug effects; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000077944:Alefacept; D000068800:Etanercept; C472181:efalizumab